CCL27 and brain cancer: Existing evidence, presented in this review, demonstrates a rapidly evolving NK cell and ILC research field and proposes that continued research efforts will lead to the development and refinement of NK- and ILC-based therapies which can be used in combination with existing standard and novel oncolytic virus and drug-based therapies to meaningfully enhance brain cancer patient outcomes.